[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.249.15. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Oncology Clinical Evidence Synopsis
April 2018

Pathogen-Reduced Platelets for the Prevention of Bleeding in People of Any Age

Author Affiliations
  • 1NHS Blood and Transplant, National Institute for Health Research (NIHR), Oxford, England
  • 2Oxford Biomedical Research Centre; Radcliffe Department of Medicine, University of Oxford, Oxford, England
  • 3National Perinatal Epidemiology Unit (NPEU), University of Oxford, Old Road Campus, Oxford, England
  • 4Oxford University Hospitals, Oxford, England
JAMA Oncol. 2018;4(4):571-572. doi:10.1001/jamaoncol.2017.5049
Abstract

Clinical Question  Are pathogen-reduced platelets as effective as standard platelets for the prevention of bleeding in people of any age requiring platelet transfusions?

Bottom Line  In people with cancer who have a low platelet count due to their disease or its treatment, pathogen-reduced platelet transfusions increase risk of platelet refractoriness and platelet transfusion requirement (high-quality evidence) but probably do not effect all-cause mortality, risk of clinically significant or severe bleeding, or risk of a serious adverse event (moderate-quality evidence). There was insufficient evidence for people with other diagnoses.

×